Elecoglipron (also referenced in some trial registries as AZD5004) is AstraZeneca's oral small-molecule, non-peptide GLP-1 receptor agonist — a chemically distinct approach from peptide-based oral formulations like semaglutide, which require specific absorption enhancers to survive the digestive tract. On June 8, 2026, AstraZeneca presented positive Phase 2b results from two trials, SOLSTICE and VISTA, at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, with both trials simultaneously published in The Lancet.[1][2]
SOLSTICE: type 2 diabetes
SOLSTICE enrolled 404 adults with type 2 diabetes and inadequate glycemic control. Participants receiving elecoglipron 75mg achieved a mean HbA1c reduction of 1.9 percentage points from baseline at 26 weeks, compared to 0.2 percentage points with placebo — the trial's primary endpoint, met with clinical and statistical significance.[1] By week 26, 90% of participants on the 75mg dose reached an HbA1c below 7%, and 85% reached 6.5% or lower — both standard guideline-recommended glycemic targets.
VISTA: obesity and overweight
VISTA enrolled 310 adults with obesity or overweight plus at least one weight-related comorbidity. At the co-primary endpoint of achieving at least 5% weight loss by week 26, 88.8% of the elecoglipron group met that threshold versus 15.6% of the placebo group.[2] Reported weight loss figures vary somewhat by dose and timepoint across coverage of the trial: up to 10.5% body weight loss at 26 weeks with the 75mg dose in some reporting, and up to 11.8% at 36 weeks in longer-timepoint reporting. VISTA participants also showed reductions in blood pressure and markers of systemic inflammation alongside the weight loss.[3]
In the SOLSTICE trial, the significant HbA1c and weight loss results achieved with elecoglipron show its potential to become an important treatment option for people with type 2 diabetes.
Safety profile
Adverse event rates across elecoglipron dose groups in the trials ranged from 84% to 98%, compared to 84% in the placebo group.[3] The most common events were nausea, constipation, diarrhea, and headache — consistent with the known tolerability profile of the GLP-1 receptor agonist class generally, whether peptide or small-molecule.
Why a small-molecule mechanism matters
Existing oral GLP-1 options, including oral semaglutide, are peptide-based and require specific formulation strategies (such as an absorption enhancer) to survive the digestive tract intact, which historically has meant strict dosing conditions like fasting and delayed food intake. A small-molecule, non-peptide GLP-1 receptor agonist is chemically simpler to formulate and may avoid some of those administration constraints, though elecoglipron's specific dosing requirements should be confirmed against final labeling once available, as Phase 2b protocols do not necessarily reflect eventual approved dosing instructions.
What comes next
AstraZeneca has advanced elecoglipron into an extensive Phase III program spanning obesity and type 2 diabetes, including dedicated cardiovascular and kidney outcome trials.[3] Phase III outcome trials are a materially higher evidentiary bar than Phase 2b efficacy data — they're designed to establish long-term safety and hard clinical endpoints (cardiovascular events, kidney function decline) rather than the surrogate endpoints (HbA1c, body weight percentage) that Phase 2b trials are built around.
Phase 2b results do not guarantee Phase III success. Efficacy and safety signals at this stage are promising but not definitive — the drug development literature includes many Phase 2 successes that did not replicate in larger, longer Phase III programs.
Elecoglipron is not yet approved for any indication and has no confirmed market timeline. Phase III programs for cardiometabolic drugs typically run multiple years before regulatory submission.
Competitive context
Elecoglipron enters a rapidly consolidating oral GLP-1 field. Novo Nordisk's oral Wegovy (semaglutide) received approval in December 2025, and Eli Lilly's Foundayo (orforglipron) received FDA approval on April 1, 2026.[3] Other companies, including Structure Therapeutics and Vincentage Pharma, have late-stage oral GLP-1 receptor agonist programs in development, indicating the oral-format segment of this drug class is becoming genuinely competitive rather than dominated by a single entrant.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.